Genetic Variation in *CYP17A1* and Pancreatic Cancer in a Population-Based Case-Control Study in the San Francisco Bay Area, California

Eric J Duell[1,2,3], **Elizabeth A Holly**[4], **Karl T Kelsey**[5], and **Paige M Bracci**[4]

[1] Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Barcelona, Spain [2] International Agency for Research on Cancer, Lyon, France [3] Norris Cotton Cancer Center, Section of Biostatistics & Epidemiology, Department of Community & Family Medicine, Dartmouth Medical School, Lebanon, New Hampshire [4] Division of Cancer Epidemiology, Department of Epidemiology and Biostatistics, University of California, San Francisco, California [5] Departments of Community Health and Pathology and Laboratory Medicine, Center for Environmental Health and Technology, Brown University, Providence, Rhode Island

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death in men and women in the U.S. Reproductive factors and steroid hormones have been suspected risk factors for many years, but the results from epidemiologic studies to date have been inconclusive. *CYP17A1* encodes cytochrome P450c17α, an enzyme with 17α-hydroxylase and 17,20-lyase activities in estradiol biosynthesis. A polymorphism in the 5'UTR promoter region of *CYP17A1* −34T/C(A1/A2) has been associated with circulating estrogens in pre-menopausal women and with susceptibility to breast, prostate, and endometrial cancer. Questionnaire data and germ-line DNA collected in a San Francisco Bay Area population-based case-control study of pancreatic cancer (cases=532, controls=1701) were used to conduct analyses of pancreatic cancer susceptibility related to the *CYP17A1* polymorphism and whether effects associated with smoking and reproductive risk factors were modified by this polymorphism. Mass spectrometry-and TaqMan-based methods were used to determine *CYP17A1* genotypes in DNA samples from 308 cases and 964 controls. Results showed that carriers of the A2 allele (vs. A1/A1) were significantly less likely to have been diagnosed with pancreatic cancer (A1/A2, adjusted odds ratio (OR)=0.77, 95% confidence interval (CI)=0.58-1.0; A2/A2, OR=0.63, 95%CI=0.42-0.93; *p*-trend=0.01). ORs for *CYP17A1* genotypes did not differ by sex, but the observed inverse association was stronger in post-menopausal women. ORs for smoking and pancreatic cancer were not modified by *CYP17A1*

Corresponding author: Eric J Duell, Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Avda Gran Via 199-203 08907 L'Hospitalet de Llobregat, Barcelona, Spain. Tel +34 93 260 74 01, Fax +34 93 260 77 87, eduell@iconcologia.net.

genotype. Our results suggest that the *CYP17A1* A2 allele may be associated with a lower risk of pancreatic cancer in both men and women.

Introduction

Pancreatic cancer is the fourth leading cause of cancer death in the US (1). Few environmental risk factors have been identified including smoking and some dietary factors (2;3). Incidence rates are approximately 25-50% higher in men than in women, but this difference becomes less marked at older ages (>75 years) (2). Combined with evidence from cell line and animal studies, these data have been used as a rationale to investigate the association between pancreatic cancer and hormonal and reproductive factors (4-7). However, the results from most studies (8-30) have been inconclusive partially due to design and analysis methods such as the use of proxy data in earlier studies, inconsistencies in analytic approach, small sample size, and inadequate control for smoking and other potential confounders.

Cytochrome P450c17alpha (*CYP17A1*) is located in the 10q24.32 chromosomal region and encodes cytochrome P450c17α, an enzyme with 17α-hydroxylase and 17,20-lyase activities at branch points in estrogen and testosterone biosynthesis (31). One extensively studied polymorphism in *CYP17A1* (−34T/C, A1/A2, rs743572) is located in the 5'untranslated promoter region (32). The *CYP17A1* −34C (A2) allele was reported to result in higher P450c17α mRNA levels (32) and possibly higher endogenous levels of sex steroids. However, results from studies that have evaluated the functional effects of *CYP17A1* alleles have been inconsistent (31;33;34). *CYP17A1* A2 genotypes may influence circulating estrogen levels, but this appears to be limited to premenopausal women (31;34-37). A number of studies have reported an association between this polymorphism and age at menarche and estrogen use (31). Finally, the *CYP17A1* A2 allele has been associated with the hormone-related cancers endometrial (A2 allele associated with lower risk, OR range 0.62 to 0.44 based on five studies each with fewer than 200 cases, and no association for one study with 497 cases), breast (A2 allele associated with a slight increased risk, summary OR=1.05; 95% CI=0.87-1.21 based on 15 case-control studies) and prostate (A2 associated with increased risk in men of African descent, summary OR=1.56; 95% CI=1.07-2.28, based on three studies) (34;36;38-43).

The association between the *CYP17A1* −34 C/T (A1/A2) polymorphism and pancreatic cancer was investigated as a follow-up to previous analyses of reproductive factors and pancreatic cancer risk in our large population-based case-control study in the San Francisco Bay Area (11). Here, we determined the main effects of the *CYP17A1* polymorphism with pancreatic cancer as well as potential gene-environment interactions with smoking and reproductive factors in patients with ductal adenocarcinoma of the pancreas and population-based controls.

Methods

Population

A population-based case-control study of pancreatic cancer was conducted in six San Francisco Bay Area counties (Alameda, Contra Costa, Marin, San Francisco, San Mateo, and Santa Clara) between 1994 and 2005. Detailed methods on the study design and selection methods for the full study have been previously published (11;44-49). Briefly, cases with ductal adenocarcinoma of the pancreas diagnosed in 1995 to 1999 were identified using rapid case ascertainment at the Northern California Cancer Center with the goal of ascertaining cases within one month of pancreatic cancer diagnosis. Cases were between 21 and 85 years of age, resided in one of the six counties at diagnosis, were alive when first contacted, and were able to complete an interview in English. A total of 532 eligible cases completed the interview for a 67% response rate (47-49). Cancer diagnoses were confirmed using the Surveillance, Epidemiology, and End Results abstracts and by participants' physicians.

Control participants were identified using random-digit dial and were frequency matched to the cases in an approximate 3:1 ratio by sex and 5-year age group. Eligibility criteria were identical for control and case participants with the exception of pancreatic cancer status. Recruitment for controls older than 65 years was supplemented using Health Care Finance Administration (now Center for Medicare and Medicaid Services) lists for the six Bay Area counties. A total of 1,701 eligible control participants completed the interview for a 67% response rate (47-49).

The present analyses are based on 308 cases and 964 controls who gave a blood sample as part of the laboratory protocol of the parent study. Detailed methods for the laboratory part of the study, including a detailed comparison of participants who gave blood and those who did not, have been previously published (50-53). The study interviewers obtained separate written informed consent from all participants before conducting the interview or venipuncture. Study methods and protocols were approved by the University of California Committee on Human Research.

Exposure and demographic information were obtained from the participants during in-person interviews conducted by trained interviewers using structured questionnaires. No proxy interviews were conducted. Race groups were based on self-report and defined as white or Caucasian, black or African American, Asian or other (5 cases, 15 controls of mixed race). Results are not presented separately for 'other race' due to sparse data. Smokers were those who had smoked more than 100 cigarettes in their lifetime and had smoked cigars or pipes at least once per month for six months or more. Never smokers who reported a history of involuntary (passive) smoking at home as an adult (women: 32 cases, 95 controls; men: 5 cases, 21 controls) were combined with former active smokers and pipe or cigar smokers to form three groups (never, former, and current) used in analyses of smoking status.

Laboratory

Genomic DNA was extracted from whole blood using the QIAmp DNA Blood Mini kit. *CYP17A1* −34 C/T (A1/A2) (*rs*743572) genotyping was performed using a mass spectrometry method (MassCode™, Qiagen Genomics, Inc) and was repeated on a 10% random sample of DNA specimens and found to be discordant in 3 out of 128 pairs. MassCode genotyping resulted in no-calls for 8.4% of cases and 4.2% of controls. Specimens that did not replicate or that were "no calls" (plus a random 5%) were repeated using a previously designed TaqMan™ assay. After repeat genotyping, all no-calls and discordant genotypes were resolved; thus, there were no missing values for *CYP17A1* genotypes used in these analyses.

Statistical Analysis

Tests for Hardy-Weinberg equilibrium among controls were conducted using observed genotype frequencies and a χ^2 test with one degree of freedom. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated using unconditional logistic regression in SAS (version 9.1, SAS Institute). All models were adjusted for age and sex, the frequency-matched variables. Tests for trend were based on the chi-square p-value from the adjusted unconditional logistic regression models where genotype was included as an ordinal variable representing the number of variant alleles present, e.g. 0, 1, 2. False positive report probabilities (FPRP) were provided for a range of priors (0.01 to 0.1) based on previous reports of associations of the 5'UTR A1/A2 polymorphism with cancer and the existence of functional data (31;34;37;38;40-42;54;55), and assuming FPRP noteworthiness at values below 0.5 (56). For ease of presentation, interactions (departures from multiplicative effects) were evaluated using stratified methods. Continuous variables for reproductive factors were compared across *CYP17A1* genotypes using a Kruskal-Wallis test. The following reproductive factors were evaluated as continuous variables in analyses to detect differences by *CYP17A1* genotype in control women: age at menarche (years), age at menopause (years), age at first use of oral contraceptives (OC, years), age at first use of estrogen replacement therapy (ERT, years), total duration of OC use (months), and body mass index (BMI, kg/m^2).

Results

The *CYP17A1* 5'UTR −34 T/C polymorphism satisfied Hardy-Weinberg equilibrium for each control group by race (all *p*-values >0.1, data not shown). The *CYP17A1* 5'UTR polymorphism was inversely associated with pancreatic cancer in all participants combined (adjusted for age, sex, race, and smoking status) (Table 1), and in each group by race [adjusted for age, sex, and smoking status, in African Americans: A1/A2 OR = 0.39, 95% CI = 0.12-1.3; A2/A2 OR = 0.16, 95% CI = 0.03-1.0 (both compared to A1/A1); in Asian Americans: A1/A2 OR = 0.33, 95% CI = 0.08-1.5; A2/A2 OR = 0.49, 95% CI = 0.11-2.1 (both compared to A1/A1)]. Decreasing trends in *CYP17A1* genotype ORs also were observed in non-Hispanic whites, and in participants under 70 years of age (Table 1), but not among those 70+ years of age (data not shown). Consistent inverse associations were observed by sex, and were somewhat stronger in post-menopausal women (Table 2). Although smoking was not a confounder of the associations between *CYP17A1* genotype

and pancreatic cancer, we kept this variable in all final models since it is an established risk factor.

False positive report probabilities (FPRP) for the associations between A2/A2 and pancreatic cancer reported in Table 1 were as follows (for prior probabilities ranging from 0.01 to 0.1) for all participants (FPRP = 0.769, 0.232); for non-Hispanic whites (FPRP = 0.908, 0.474); and for participants <70 yr. (FPRP = 0.798, 0.264). For the lower range of priors (0.01), these results were not considered noteworthy (all FPRP >0.5), but for the higher end of the range of priors (0.1), the results were all considered noteworthy (all FPRP <0.5). FPRP values for the associations between A2/A2 and pancreatic cancer reported in Table 2 were as follows (for prior probabilities ranging from 0.01 to 0.1) for all women (FPRP = 0.953, 0.648); for postmenopausal women (FPRP = 0.854, 0.348); and for men (FPRP = 0.908, 0.474). For the lower range of priors (0.01), the results in Table 2 were not noteworthy (all FPRP >0.5). For the higher end of the range of priors (0.1), the results were noteworthy in postmenopausal women and in men (all FPRP <0.5), but not in all women (FPRP >0.5).

Mean or median age at menarche (in years), age at menopause, age at first OC use, and body-mass index (kg/m^2) were independent of *CYP17A1* genotypes in control women (data not shown). A shorter mean total duration of OC use was observed in control women with the *CYP17A1* A2 allele (A1/A1: 58.7 months; A1/A2: 48.6 months; A2/A2: 47.1 months), although differences in duration of use could have been due to chance (*p*-value=0.6).

Odds ratios for smoking status and pancreatic cancer were not modified by *CYP17A1* genotype (Table 3). In analyses of ERT and oral contraceptives (OC) used either alone or in combination (stratified by *CYP17A1* genotype), there was some suggestion of an inverse association (in all women and in postmenopausal women) with a combination of A2 allele genotypes and exogenous hormone use, although estimates were imprecise (Table 3).

Discussion

Our analyses of the *CYP17A1* 5'UTR −34 T/C (A1/A2) polymorphism and pancreatic cancer showed that the A2 allele conferred a 23 to 37% decreased risk. These results were consistent across race groups and observed in both men and postmenopausal women.

If *CYP17A1* A2 is associated with an increase in endogenous hormone levels such as estradiol, then our observation of an inverse association between this allele and pancreatic cancer risk would provide support for the hypothesis that estrogens reduce the risk of pancreatic cancer. However, results from several studies showed little or no association between *CYP17A1* A2 genotypes and levels of sex steroids, except possibly in younger premenopausal women (31;34-37).

Associations between *CYP17A1* A2 genotypes have been observed in several hormone-related cancers including endometrial (34), and breast in women (38;39;57), and prostate cancer in men of African ancestry (43;58). Some studies of *CYP17A1* and breast cancer have reported interactions with reproductive factors, ERT use and BMI (38;57). A number of studies have reported associations between *CYP17A1* A2 and earlier age at menarche (31), and a recent Swedish study found associations with menstrual cycle length, age at first use

of OC, and *BRCA* non-carrier mutation status in women from known *BRCA1/2* families (54). In contrast, among women in our study population, there were no statistically significant associations between *CYP17A1* genotypes and self-reported age at menarche, age at menopause, age of first OC use, age of first ERT use, duration of OC use, and BMI.

The putative functional effect of *CYP17A1* alleles, whether in LD or not, may be more subtle than a direct effect on serum hormone levels. Tissue specificity for *CYP17A1* or other hormone metabolites and pathways are likely to be involved. For example, 2-methoxyestradiol, an endogenous metabolite of 17β-estradiol can trigger pancreatic cancer cells to up-regulate cell death pathways (59).

We cannot rule out the potential for recall bias and measurement error related to poor recall of past events (such as ages at menarche or menopause, or exogenous hormone use). Replication of these results in other study populations, and analyses of pooled data from pancreatic cancer consortia are needed to confirm or refute a possible role of the *CYP17A1* A2 allele in pancreatic cancer etiology

Acknowledgments

Reference List

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. Mar; 2008 58(2):71–96. [PubMed: 18287387]

2. Anderson, KE.; Mack, TM.; Silverman, DT. Cancer of the pancreas.. In: Schottenfeld, D.; Fraumeni, JF., Jr, editors. Cancer Epidemiology and Prevention. 3rd ed.. Oxford University Press; New York: 2006. p. 721-62.

3. Duell, EJ.; Bracci, PM.; Holly, EA. Environmental Determinants of Exocrine Pancreatic Cancer.. In: Pour, PM., editor. Toxicology of the Pancreas. CRC Press; Boca Raton: 2006. p. 395-422.

4. Benz C, Hollander C, Miller B. Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res. May; 1986 46(5):2276–81. [PubMed: 3697973]

5. Bourhis J, Lacaine F, Augusti M, Huguier M. Protective effect of oestrogen in pancreatic cancer. Lancet. Oct 24.1987 2(8565):977. [PubMed: 2889905]

6. Longnecker DS, Sumi C. Effects of sex steroid hormones on pancreatic cancer in the rat. Int J Pancreatol. Aug; 1990 7(1-3):159–65. [PubMed: 2081921]

7. Longnecker DS. Hormones and pancreatic cancer. Int J Pancreatol. 1991; 9:81–6. [PubMed: 1744451]

8. Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer. Nov 15; 1989 44(5):833–9. [PubMed: 2583865]

9. Bueno de Mesquita HB, Maisonneuve P, Moerman CJ, Walker AM. Anthropometric and reproductive variables and exocrine carcinoma of the pancreas: a population-based case-control study in The Netherlands. Int J Cancer. Aug 19; 1992 52(1):24–9. [PubMed: 1500223]

10. Cantor KP, Lynch CF, Johnson D. Reproductive factors and risk of brain, colon, and other malignancies in Iowa (United States). Cancer Causes Control. Nov; 1993 4(6):505–11. [PubMed: 8280827]

11. Duell EJ, Holly EA. Reproductive and menstrual risk factors for pancreatic cancer: a population-based study of San Francisco Bay Area women. Am J Epidemiol. Apr 15; 2005 161(8):741–7. [PubMed: 15800266]

12. Fernandez E, La Vecchia C, d'Avanzo B, Negri E. Menstrual and reproductive factors and pancreatic cancer risk in women. Int J Cancer. Jul 4; 1995 62(1):11–4. [PubMed: 7601558]

13. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer. Jun 20; 2003 105(3):408–12. [PubMed: 12704678]

14. Haines AP, Moss AR, Whittemore A, Quivey J. A case-control study of pancreatic carcinoma. J Cancer Res Clin Oncol. 1982; 103(1):93–7. [PubMed: 7076720]

15. Heuch I, Jacobsen BK, Albrektsen G, Kvale G. Reproductive factors and pancreatic cancer risk: a Norwegian cohort study. Br J Cancer. Jan 15; 2008 98(1):189–93. [PubMed: 18000501]

16. Ji BT, Hatch MC, Chow WH, McLaughlin JK, Dai Q, Howe GR, Gao YT, Fraumeni JF Jr. Anthropometric and reproductive factors and the risk of pancreatic cancer: a case-control study in Shanghai, China. Int J Cancer. May 16; 1996 66(4):432–7. [PubMed: 8635856]

17. Kalapothaki V, Tzonou A, Hsieh CC, Toupadaki N, Karakatsani A, Trichopoulos D. Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control. Jul; 1993 4(4):375–82. [PubMed: 8347787]

18. Karlson BM, Wuu J, Hsieh CC, Lambe M, Ekbom A. Parity and the risk of pancreatic cancer: a nested case-control study. Int J Cancer. Jul 17; 1998 77(2):224–7. [PubMed: 9650557]

19. Kreiger N, Lacroix J, Sloan M. Hormonal factors and pancreatic cancer in women. Ann Epidemiol. Nov; 2001 11(8):563–7. [PubMed: 11709276]

20. Kvale G, Heuch I, Nilssen S. Parity in relation to mortality and cancer incidence: a prospective study of Norwegian women. Int J Epidemiol. Aug; 1994 23(4):691–9. [PubMed: 8002181]

21. La Vecchia C, Negri E, Franceschi S, Parazzini F. Long-term impact of reproductive factors on cancer risk. Int J Cancer. Jan 21; 1993 53(2):215–9. [PubMed: 8425757]

22. Lin RS, Kessler II. A multifactorial model for pancreatic cancer in man. Epidemiologic evidence. JAMA. Jan 9; 1981 245(2):147–52. [PubMed: 7452829]

23. Lin Y, Kikuchi S, Tamakoshi A, Kawamura T, Inaba Y, Kurosawa M, Motohashi Y, Yagyu K, Obata Y, Ishibashi T. Association of menstrual and reproductive factors with pancreatic cancer risk in women: findings of the Japan Collaborative Cohort Study for Evaluation of Cancer Risk. J Gastroenterol. Sep; 2006 41(9):878–83. [PubMed: 17048052]

24. Lo AC, Soliman AS, El Ghawalby N, Abdel-Wahab M, Fathy O, Khaled HM, Omar S, Hamilton SR, Greenson JK, Abbruzzese JL. Lifestyle, occupational, and reproductive factors in relation to pancreatic cancer risk. Pancreas. Aug; 2007 35(2):120–9. [PubMed: 17632317]

25. Mack TM, Yu MC, Hanisch R, Henderson BE. Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst. Jan; 1986 76(1):49–60. [PubMed: 3455742]

26. Navarro Silvera SA, Miller AB, Rohan TE. Hormonal and reproductive factors and pancreatic cancer risk: a prospective cohort study. Pancreas. May; 2005 30(4):369–74. [PubMed: 15841050]

27. Prizment AE, Anderson KE, Hong CP, Folsom AR. Pancreatic cancer incidence in relation to female reproductive factors: Iowa Women's Health Study. JOP. 2007; 8(1):16–27. [PubMed: 17228129]

28. Skinner HG, Michaud DS, Colditz GA, Giovannucci EL, Stampfer MJ, Willett WC, Fuchs CS. Parity, reproductive factors, and the risk of pancreatic cancer in women. Cancer Epidemiol Biomarkers Prev. May; 2003 12(5):433–8. [PubMed: 12750238]

29. Teras LR, Patel AV, Rodriguez C, Thun MJ, Calle EE. Parity, other reproductive factors, and risk of pancreatic cancer mortality in a large cohort of U.S. women (United States). Cancer Causes Control. Nov; 2005 16(9):1035–40. [PubMed: 16184468]

30. Wynder EL, Mabuchi K, Maruchi N, Fortner JG. A case control study of cancer of the pancreas. Cancer. Mar; 1973 31(3):641–8. [PubMed: 4693593]

31. Sharp L, Cardy AH, Cotton SC, Little J. CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. a HuGE review. Am J Epidemiol. Oct 15; 2004 160(8):729–40. [PubMed: 15466495]

32. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. Oct; 1994 3(10):1873–6. [PubMed: 7849715]

33. Nedelcheva K,V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res. Jun 15; 1999 59(12):2825–8. [PubMed: 10383140]

34. Olson SH, Bandera EV, Orlow I. Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am J Epidemiol. Feb 1; 2007 165(3):235–45. [PubMed: 17110639]

35. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. Feb 15; 1998 58(4):585–7. [PubMed: 9485002]

36. Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. Nov; 2007 16(11):2237–46. [PubMed: 18006912]

37. Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. Jan; 2004 13(1):94–101. [PubMed: 14744739]

38. Chen Y, Gammon MD, Teitelbaum SL, Britton JA, Terry MB, Shantakumar S, Eng SM, Wang Q, Gurvich I, Neugut AI, Santella RM, Ahsan H. Estrogen biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project. Carcinogenesis. Apr; 2008 29(4):766–71. [PubMed: 18281250]

39. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. Mar 15; 1997 57(6):1063–5. [PubMed: 9067272]

40. Feigelson HS, McKean-Cowdin R, Henderson BE. Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis. Sep; 2002 17(5):445–6. [PubMed: 12202634]

41. Gaudet MM, Lacey JV Jr. Lissowska J, Peplonska B, Brinton LA, Chanock S, Garcia-Closas M. Genetic variation in CYP17 and endometrial cancer risk. Hum Genet. Mar; 2008 123(2):155–62. [PubMed: 18172694]

42. Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. Feb; 2003 12(2):120–6. [PubMed: 12582021]

43. Sarma AV, Dunn RL, Lange LA, Ray A, Wang Y, Lange EM, Cooney KA. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate. Feb 15; 2008 68(3):296–305. [PubMed: 18163429]

44. Chan JM, Wang F, Holly EA. Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco bay area. Cancer Epidemiol Biomarkers Prev. Sep; 2005 14(9):2093–7. [PubMed: 16172215]

45. Chan JM, Wang F, Holly EA. Whole grains and risk of pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area, California. Am J Epidemiol. Nov 15; 2007 166(10):1174–85. [PubMed: 17881383]

46. Chan JM, Wang F, Holly EA. Pancreatic cancer, animal protein and dietary fat in a population-based study, San Francisco Bay Area, California. Cancer Causes Control. Dec; 2007 18(10):1153–67. [PubMed: 17805983]

47. Eberle CA, Bracci PM, Holly EA. Anthropometric factors and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. Cancer Causes Control. Dec; 2005 16(10):1235–44. [PubMed: 16215874]

48. Holly EA, Eberle CA, Bracci PM. Prior history of allergies and pancreatic cancer in the San Francisco Bay area. Am J Epidemiol. Sep 1; 2003 158(5):432–41. [PubMed: 12936898]

49. Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev. Aug; 2006 15(8):1458–63. [PubMed: 16896032]

50. Duell EJ, Holly EA, Bracci PM, Liu M, Wiencke JK, Kelsey KT. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst. Feb 20; 2002 94(4):297–306. [PubMed: 11854392]

51. Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. Apr; 2006 15(4):726–31. [PubMed: 16614115]

52. Duell EJ, Bracci PM, Moore JH, Burk RD, Kelsey KT, Holly EA. Detecting pathway-based gene-gene and gene-environment interactions in pancreatic cancer. Cancer Epidemiol Biomarkers Prev. Jun; 2008 17(6):1470–9. [PubMed: 18559563]

53. Duell EJ, Holly EA, Bracci PM, Wiencke JK, Kelsey KT. A Population-based Study of the Arg399Gln Polymorphism in X-Ray Repair Cross- Complementing Group 1 (XRCC1) and Risk of Pancreatic Adenocarcinoma. Cancer Res. Aug 15; 2002 62(16):4630–6. [PubMed: 12183419]

54. Henningson M, Johansson U, Borg A, Olsson H, Jernstrom H. CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women. Mol Hum Reprod. Apr; 2007 13(4):231–6. [PubMed: 17307805]

55. Jasienska G, Kapiszewska M, Ellison PT, Kalemba-Drozdz M, Nenko I, Thune I, Ziomkiewicz A. CYP17 genotypes differ in salivary 17-beta estradiol levels: a study based on hormonal profiles from entire menstrual cycles. Cancer Epidemiol Biomarkers Prev. Nov; 2006 15(11):2131–5. [PubMed: 17119038]

56. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. Mar 17; 2004 96(6):434–42. [PubMed: 15026468]

57. Wu AH, Seow A, Arakawa K, Van Den BD, Lee HP, Yu MC. HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer. Apr 20; 2003 104(4):450–7. [PubMed: 12584742]

58. Lindstrom S, Zheng SL, Wiklund F, Jonsson BA, Adami HO, Balter KA, Brookes AJ, Sun J, Chang BL, Liu W, Li G, Isaacs WB, et al. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate. Dec 1; 2006 66(16):1729–43. [PubMed: 16998812]

59. Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res. Apr 15; 2006 66(8):4309–18. [PubMed: 16618756]

Table 1

Odds ratios for *CYP17A1* and pancreatic cancer, San Francisco Bay Area, California 1995-1999

	All Participants			Non-Hispanic White			<70 yr		
	Cases	Controls		Cases	Controls		Cases	Controls	
	n	n	OR [*] (95% CI)	n	n	OR [**] (95% CI)	n	n	OR [*] (95% CI)
*CYP17A1 5'*UTR									
A1/A1	131	339	1.0 (referent)	101	287	1.0 (referent)	81	207	1.0 (referent)
A1/A2	133	440	0.77 (0.58-1.0)	113	372	0.82 (0.60-1.1)	83	259	0.80 (0.55-1.2)
A2/A2	44	185	0.63 (0.42-0.93)	32	141	0.66 (0.42-1.0)	27	127	0.55 (0.33-0.91)
p-trend			0.01			0.06			0.02

[*]
Adjusted for age, sex race and smoking status.

[**]
Adjusted for age, sex and smoking status.

Table 2

Odds ratios for *CYP17A1* and pancreatic cancer by sex, San Francisco Bay Area, California 1995–1999

	All Women			Post-Menopausal Women			Men		
	Cases	Controls		Cases	Controls		Cases	Controls	
	n	n	OR * (95% CI)	n	n	OR * (95% CI)	n	n	OR * (95% CI)
*CYP17A1 5'*UTR									
A1/A1	60	156	1.0 (referent)	57	138	1.0 (referent)	71	183	1.0 (referent)
A1/A2	61	197	0.80 (0.52-1.2)	58	167	0.82 (0.53-1.3)	72	243	0.73 (0.50-1.1)
A2/A2	19	79	0.62 (0.34-1.1)	14	68	0.48 (0.24-0.93)	25	106	0.62 (0.37-1.0)
p-trend			0.1			0.04			0.05

*
Adjusted for age, race and smoking status.

Table 3

Odds ratios for smoking status and exogenous hormone use and pancreatic cancer, by *CYP17A1* genotype, San Francisco Bay Area, California 1995-1999

	CYP17A1 A1/A1		CYP17A1 A1/A2 +A2/A2	
	Cases/Controls	OR (95% CI)	Cases/Controls	OR (95% CI)
Men and Women *				
Smoking status				
Never	21/80	1.0 (referent)	26/128	1.0 (referent)
Former	83/221	1.4 (0.79-2.4)	108/419	1.2 (0.77-2.0)
Current	27/38	2.7 (1.3-5.5)	43/78	2.7 (1.5-4.7)
All women **				
ERT/OC Use				
Neither	12/29	1.0 (referent)	21/50	1.0 (referent)
OC only	10/30	1.0 (0.31-3.4)	19/53	1.1 (0.46-2.7)
ERT only	21/51	1.0 (0.43-2.4)	21/75	0.67 (0.33-1.4)
ERT and OC	16/43	1.1 (0.40-2.8)	18/91	0.55 (0.25-1.2)
p-trend		0.6		0.04
Postmenopausal women **				
ERT/OC Use				
Neither	12/27	1.0 (referent)	20/42	1.0 (referent)
OC only	7/17	1.1 (0.31-4.2)	12/26	0.95 (0.34-2.6)
ERT only	21/50	1.0 (0.41-2.5)	21/74	0.61 (0.29-1.3)
ERT and OC	16/41	1.2 (0.40-3.5)	18/86	0.45 (0.18-1.1)
p-trend		0.8		0.03

ERT, estrogen replacement therapy; OC, oral contraceptive

*
OR adjusted for age, sex and race.

**
Adjusted for age, race and smoking status.